- Home
- RLX vs IOVA Comparison
RLX vs IOVA Comparison
Compare RLX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- IOVA
- Stock Information
- Founded
- RLX 2018
- IOVA 2007
- Country
- RLX China
- IOVA United States
- Employees
- RLX N/A
- IOVA N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLX Health Care
- IOVA Health Care
- Exchange
- RLX Nasdaq
- IOVA Nasdaq
- Market Cap
- RLX 3.6B
- IOVA 771.4M
- IPO Year
- RLX 2021
- IOVA N/A
- Fundamental
- Price
- RLX $2.40
- IOVA $1.74
- Analyst Decision
- RLX Hold
- IOVA Buy
- Analyst Count
- RLX 1
- IOVA 10
- Target Price
- RLX $2.25
- IOVA $12.22
- AVG Volume (30 Days)
- RLX 4.1M
- IOVA 11.7M
- Earning Date
- RLX 08-15-2025
- IOVA 08-07-2025
- Dividend Yield
- RLX 0.42%
- IOVA N/A
- EPS Growth
- RLX N/A
- IOVA N/A
- EPS
- RLX 0.07
- IOVA N/A
- Revenue
- RLX $369,684,697.00
- IOVA $212,679,000.00
- Revenue This Year
- RLX $27.26
- IOVA $86.62
- Revenue Next Year
- RLX $19.61
- IOVA $69.95
- P/E Ratio
- RLX $34.98
- IOVA N/A
- Revenue Growth
- RLX 68.72
- IOVA 11070.12
- 52 Week Low
- RLX $1.50
- IOVA $1.64
- 52 Week High
- RLX $2.69
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- RLX 79.05
- IOVA 38.67
- Support Level
- RLX $2.19
- IOVA $1.67
- Resistance Level
- RLX $2.20
- IOVA $1.82
- Average True Range (ATR)
- RLX 0.07
- IOVA 0.12
- MACD
- RLX 0.02
- IOVA -0.00
- Stochastic Oscillator
- RLX 100.00
- IOVA 13.85
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.